Bronchial hyperresponsiveness, or airway hyperresponsiveness to acknowledge incomplete understanding of the precise anatomical site involved, is an exaggerated constrictor response to various stimuli. Airway hyperresponsiveness has been recognised for over 50 years and, although associated with a number of bronchial diseases, is considered a key feature of asthma which correlates with severity of disease, frequency of symptoms, and need for treatment.' Asthma is characterised by spontaneous changes in airway calibre which can be documented by serial peak flow measurements. Wide variation in airflow limitation is an index of asthma severity and patients with considerable diurnal variation in peak flow are susceptible to acute bronchoconstriction to environmental stimuli. The extent of susceptibility can be assessed in the laboratory by bronchoconstrictor challenge tests which measure the responsiveness of the airways. Inhalation of histamine or methacholine is a commonly used challenge with the concentration of spasmogen provoking a 20% fall in forced expiratory volume in one second (PC2OFEV,) used as an index of airway responsiveness.
The pathogenesis of airway hyperresponsiveness is unclear, although in asthma it is linked with inflammation. 2 clinically normal subjects exhibited airway hyperresponsiveness, defined by a PC20FEV, to histamine of < 8 mg/ml, in the absence of any inflammatory cell infiltration: T lymphocytes, eosinophils, mast cells, or antigen presenting cells. The extent of activation of the inflammatory cells was not determined. The authors conclude that airway hyperresponsiveness as currently defined is independent of immunopathological changes in the bronchial wall, nor does bronchial hyperresponsiveness necessarily reflect subclinical inflammation.
Several recent studies develop the concept of normal airway responsiveness. Airway responsiveness to histamine is distributed continuously in human subjects in a log-normal manner with no clear cutoff between normal and increased airAvay responsiveness despite an arbitrary definition of hyperresponsiveness of a PC2OFEV1 to histamine of <8 mg/ml." Up to 50% of subjects with no evidence of asthma or other respiratory disease can be categorised as having mild airway hyperresponsiveness (PC2o to histamine of 2-8 mg/ml).'5 16 Thus, airway hyperresponsivness is not diagnostic of asthma; rather it is a functional disorder reflecting a tendency to airflow obstruction. In epidemiological surveys of asthma, diagnosis is based on airway hyperresponsiveness in combination with a history of wheeze in the previous year. ' 20 The underlying mechanisms are indirect, involving cellular and neural pathways which may be abnormal in asthma.2' In contrast, histamine and methacholine act directly on appropriate receptors on the airway smooth muscle which have not been shown to be abnormal in asthma.2'22 A positive bronchoconstrictor response to exercise or cold air is consistent with a diagnosis of asthma, although a negative response does not exclude asthma. Physical stimuli have a number of disadvantages: they involve dedicated and expensive laboratory equipment, cannot be administered in graded dose increments, have not been fully standardised, and are potentially more hazardous to the patient than pharmacological challenge. Assessment of airway hyperresponsiveness with indirect bronchoconstrictor stimuli, however, may provide information about pathophysiological mechanisms in asthma. For example, adenosine 5-monophosphate (a putative mast cell stimulus) and the neural stimulants bradykinin and sodium metabisulphite overcome problems of physical challenges as they are administered in a similar manner to histamine. 18 The relation between airway inflammation and airway 
